Bonjesta - (20;20 mg; Tablet, Extended Release)

Generic Name	Doxylamine succinate and Pyridoxine hydrochloride	Innovator	Duchesnay Inc
Dosage	20;20 mg; Tablet, Extended Release	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	Less Than 5	Generic Launches	None
Indication	Indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
******* (****)	*** \ *********	*** **, ****	*******	********	******* *** **** *** *** ****
*****	** \ **	*** **, ****	*******	****	******* *** **** *** *** ****

Chronology Of Events